Print Page

Letters to Healthcare Providers
 
Summary Safety Review - Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors (canagliflozin, dapagliflozin, empagliflozin) - Assessing the potential risks of prolonged or incident diabetic ketoacidosis despite stopping treatment in adult patients with type 2 diabetes (Letter to Healthcare Professionals)
 
 
 
Attachment:
  1. Summary Safety Review - Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors (canagliflozin, dapagliflozin, empagliflozin)  
Related Information:
Canada: Summary Safety Review: Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors... Posted 2024-09-27
Australia: SGLT2 inhibitors approved for T2DM only Posted 2022-02-15
SGLT2 inhibitors: monitor ketones in blood during treatment interruption for sur... Posted 2020-03-19
The United Kingdom: SGLT2 inhibitors: monitor ketones in blood during treatment ... Posted 2020-03-19
Australia: Sodium glucose co-transporter 2 inhibitors: Safety advisory - diabeti... Posted 2018-07-19
Singapore: Risk of genitourinary infections with SGLT2 inhibitors Posted 2018-05-18
Singapore: Sodium-glucose cotransporter-2 (SGLT2) inhibitors and risk of serious... Posted 2016-05-21
Canada: SGLT2 Inhibitors [INVOKANA (canagliflozin), FORXIGA (dapagliflozin), XIG... Posted 2016-05-17
The United Kingdom: SGLT2 inhibitors: updated advice on the risk of diabetic ket... Posted 2016-04-19
European Union: EMA confirms recommendations to minimise ketoacidosis risk with ... Posted 2016-02-27
Singapore: Risk of diabetic ketoacidosis associated with sodium-glucose cotransp... Posted 2016-02-25
European Union: SGLT2 inhibitors: PRAC makes recommendations to minimise risk of... Posted 2016-02-13
The United States: Drug Safety Communication: SGLT2 Inhibitors - Labels to inclu... Posted 2015-12-05
European Union: Review of diabetes medicines called SGLT2 inhibitors started - R... Posted 2015-10-12
Singapore: Interim update on risk of serious ketoacidosis associated with sodium... Posted 2015-10-08
Australia: Sodium glucose co-transporter 2 inhibitors - used to treat type 2 dia... Posted 2015-08-14
Singapore: Forxiga (dapagliflozin): Risk of diabetic ketoacidosis Posted 2015-07-22
Singapore: Invokana (canagliflozin): Risk of diabetic ketoacidosis Posted 2015-07-21
Taiwan: Risk communication on drug safety information for SGLT2 inhibitors Posted 2015-06-29
The United Kingdom: SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozi... Posted 2015-06-27
Canada: Information Update - Forxiga, Invokana: Health Canada begins safety revi... Posted 2015-06-23
The United States: Drug Safety Communication: SGLT2 inhibitors - FDA warns medic... Posted 2015-05-16
 
back